precision biosciences

sickle cell disease

Proposed Genome Editing Technology Aims to Transform SCD Treatment

Precision BioSciences will use their novel genome editing technology called ARCUS® to develop a potentially curative treatment for sickle cell disease (SCD) and other hemoglobinopathies in collaboration with Novartis Pharma. The technology will use a custom nuclease to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome. “We believe that…

Next post in SCD News Briefs